NEW YORK (Reuters) – Pfizer Inc said on Thursday it would supply 6 million courses of its Covid-19 antiviral treatment to the Global Fund, a non-governmental organization for low- and middle-income countries to address global disparities in the Covid response. want to
Paxolovid treatment courses will be available through the Global Fund’s Covid-19 Response Mechanism to 132 low- and middle-income countries this year, subject to local regulatory approvals, the company said.
While paxalovid is widely available in many rich countries, availability is severely limited in poorer ones. Pfizer said the supply agreement is part of its strategy to facilitate equitable access to oral Covid treatments.
The company has struck a deal with several generic drug makers to produce its treatment at a lower cost for developing countries.
“This agreement with the Global Fund is an important step that will increase equitable access for high-risk patients in low- and middle-income countries,” Chief Executive Officer Albert Borla said in a statement.
The Global Fund is part of the Access to Covid-19 Accelerator Partnership (ACT-A), an effort by governments and non-governmental organizations, including the World Health Organization, to procure tests, treatments and vaccines for low-income countries.